129 related articles for article (PubMed ID: 2223137)
21. Polyclonal 90Yttrium labeled antiferritin for refractory Hodgkin's disease.
Vriesendorp HM; Herpst JM; Leichner PK; Klein JL; Order SE
Int J Radiat Oncol Biol Phys; 1989 Oct; 17(4):815-21. PubMed ID: 2674084
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics of radiolabeled polyclonal antiferritin in patients with Hodgkin's disease.
Lai J; Quadri SM; Borchardt PE; Harris L; Wucher R; Askew E; Schweichel L; Vriesendorp HM
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3315s-3323s. PubMed ID: 10541380
[TBL] [Abstract][Full Text] [Related]
23. Ferritin concentration and 131I-antiferritin tumor localization in an experimental hepatoma.
Klein JL; Kopher KA; Rostock RA
Int J Radiat Oncol Biol Phys; 1986 Jan; 12(1):137-40. PubMed ID: 3943985
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma.
Juweid ME; Stadtmauer E; Hajjar G; Sharkey RM; Suleiman S; Luger S; Swayne LC; Alavi A; Goldenberg DM
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3292s-3303s. PubMed ID: 10541378
[TBL] [Abstract][Full Text] [Related]
25. Advantage of yttrium-90-labeled over iodine-131-labeled monoclonal antibodies in the treatment of a human lung carcinoma xenograft.
Stein R; Chen S; Haim S; Goldenberg DM
Cancer; 1997 Dec; 80(12 Suppl):2636-41. PubMed ID: 9406718
[TBL] [Abstract][Full Text] [Related]
26. Internal radiation therapy for patients with primary or metastatic hepatic cancer: a review.
Ho S; Lau WY; Leung TW; Johnson PJ
Cancer; 1998 Nov; 83(9):1894-907. PubMed ID: 9806647
[TBL] [Abstract][Full Text] [Related]
27. Immunoradiotherapy for primary nonresectable hepatocellular carcinoma.
Sitzmann JV; Order SE
Surg Clin North Am; 1989 Apr; 69(2):393-400. PubMed ID: 2538937
[TBL] [Abstract][Full Text] [Related]
28. The effect of iron dextran on ferritin content and 131I-antiferritin localization in experimental hepatomas.
Rostock RA; Kopher KA; Bauer TW; Klein JL
Cancer Drug Deliv; 1985; 2(1):3-9. PubMed ID: 3902193
[TBL] [Abstract][Full Text] [Related]
29. Distribution of monoclonal antiferritin antibody in Kaposi's sarcoma, Hodgkin's disease, and hepatocellular carcinoma.
Yuen AR; Higgins JP; Baker R; Kamel OW; Warnke RA; Knox SJ
Hum Pathol; 2003 Apr; 34(4):381-4. PubMed ID: 12733120
[TBL] [Abstract][Full Text] [Related]
30. Dosimetry of 131I-labeled antiferritin in hepatoma: specific activities in the tumor and liver.
Leichner PK; Klein JL; Siegelman SS; Ettinger DS; Order SE
Cancer Treat Rep; 1983; 67(7-8):647-58. PubMed ID: 6307515
[TBL] [Abstract][Full Text] [Related]
31. Radiobiology of radioimmunotherapy: targeting CD20 B-cell antigen in non-Hodgkin's lymphoma.
Hernandez MC; Knox SJ
Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1274-87. PubMed ID: 15275710
[TBL] [Abstract][Full Text] [Related]
32. Targeting of human glioma xenografts in vivo utilizing radiolabeled antibodies.
Williams JA; Wessels BW; Wharam MD; Order SE; Wanek PM; Poggenburg JK; Klein JL
Int J Radiat Oncol Biol Phys; 1990 Jun; 18(6):1367-75. PubMed ID: 2370186
[TBL] [Abstract][Full Text] [Related]
33. [Effect of radio-immunochemotherapy-using antiferritin antibody combined with anthracycline drugs on hepatocellular carcinoma cell].
Une Y; Sato Y; Alam S; Nagabuchi E; Hata Y; Uchino J
Gan To Kagaku Ryoho; 1993 Jan; 20(1):161-3. PubMed ID: 8380685
[No Abstract] [Full Text] [Related]
34. Yttrium 90-labeled antiferritin followed by high-dose chemotherapy and autologous bone marrow transplantation for poor-prognosis Hodgkin's disease.
Bierman PJ; Vose JM; Leichner PK; Quadri SM; Armitage JO; Klein JL; Abrams RA; Dicke KA; Vriesendorp HM
J Clin Oncol; 1993 Apr; 11(4):698-703. PubMed ID: 8478663
[TBL] [Abstract][Full Text] [Related]
35. Comparison of 131I- and 90Y-labeled monoclonal antibody 17-1A for treatment of human colon cancer xenografts.
Buchsbaum DJ; Lawrence TS; Roberson PL; Heidorn DB; Ten Haken RK; Steplewski Z
Int J Radiat Oncol Biol Phys; 1993 Mar; 25(4):629-38. PubMed ID: 8454481
[TBL] [Abstract][Full Text] [Related]
36. International Clinical Trials in Radiation Oncology. Isotopic immunotherapy: radiolabelled antibody.
Order SE
Int J Radiat Oncol Biol Phys; 1988; 14 Suppl 1():S77-81. PubMed ID: 3292485
[TBL] [Abstract][Full Text] [Related]
37. A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer.
Wong JY; Shibata S; Williams LE; Kwok CS; Liu A; Chu DZ; Yamauchi DM; Wilczynski S; Ikle DN; Wu AM; Yazaki PJ; Shively JE; Doroshow JH; Raubitschek AA
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5842-52. PubMed ID: 14676105
[TBL] [Abstract][Full Text] [Related]
38. Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells.
Press OW; Shan D; Howell-Clark J; Eary J; Appelbaum FR; Matthews D; King DJ; Haines AM; Hamann P; Hinman L; Shochat D; Bernstein ID
Cancer Res; 1996 May; 56(9):2123-9. PubMed ID: 8616860
[TBL] [Abstract][Full Text] [Related]
39. Radiolabeled antibody therapy for squamous cell carcinoma of the head and neck.
Shikani AH; Richtsmeier WJ; Klein JL; Kopher KA
Arch Otolaryngol Head Neck Surg; 1992 May; 118(5):521-5. PubMed ID: 1571127
[TBL] [Abstract][Full Text] [Related]
40. Radiolabeled antibodies in Hodgkin's disease.
Order SE
Cancer Treat Res; 1988; 38():223-9. PubMed ID: 2908597
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
